| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.024 | 0.6 |
| mRNA | A-443654 | GDSC1000 | pan-cancer | AAC | -0.025 | 0.6 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.6 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | TPCA-1 | GDSC1000 | pan-cancer | AAC | -0.013 | 0.6 |